UPDATE: Goldman Sachs Starts TG Therapeutics (TGTX) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TG Therapeutics (TGTX) Reports Launch of ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ (umbralisib)
April 21, 2021 7:04 AM EDTTG Therapeutics, Inc. (NASDAQ: TGTX), today announced the initiation of patient enrollment into the ULTRA-V Phase 3 randomized trial, evaluating the time-limited triple combination of UKONIQ (umbralisib), the Companys once-daily, inhibitor of PI3K-delta and CK1-epsilon, ublituximab, the Companys investigational glycoengineered anti-CD20 monoclonal antibody, and venetoclax, compared to the continuous doublet combination of UKONIQ plus ublituximab (U2) in patients with both frontline and relapsed or refractory chronic lymphocytic leukemia (CLL). The primary endpoint for the ULTRA-V Phase 3 trial is Progression-free Survival (PFS), and the trial is designed support the full approval of... More
TG Therapeutics (TGTX) PT Raised to $89 at H.C. Wainwright
April 19, 2021 6:32 AM EDTH.C. Wainwright analyst Edward P. White raised the price target on TG Therapeutics (NASDAQ: TGTX) to $89.00 (from $79.00) while maintaining a Buy rating.... More
TG Therapeutics (TGTX) Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in MS to be Presented at American Academy of Neurology 73rd Annual Meeting
April 16, 2021 7:32 AM EDTTG Therapeutics, Inc. (NASDAQ: TGTX), today announced positive results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab, the Companys investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide, in patients with relapsing forms of multiple sclerosis (RMS). Both studies met... More
